2.1 Women's perceived improvement of prolapse symptoms at 12 months (measured with PFDI‐20; range: 0‐300, higher score = worse symptoms) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.2 Women's perceived improvement of prolapse symptoms at 24 months (measured with PFDI‐20; range: 0‐300, higher score = worse symptoms) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.3 Women's perceived improvement of prolapse symptoms at 12 months (measured with POPDI‐6; range: 0‐100, higher score = worse symptoms) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.4 Women's perceived improvement of prolapse symptoms at 24 months (POPDI‐6; range: 0‐100, higher score = worse symptoms) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.5 Women's perceived improvement of prolapse symptoms at 24 months |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
2.6 Prolapse‐specific quality of life at 12 months (measured with PFIQ‐7, range: 0‐300, higher score = worse QoL) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.7 Prolapse‐specific quality of life at 24 months (measured with PFIQ‐7, range: 0‐300, higher score = worse QoL) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.8 Quality of life at 12 months (measured with PCS‐12, range: 0‐100, higher score = better health status) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.9 Quality of life at 24 months (measures with PCS‐12, range: 0‐100, higher score = better health status) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.10 Quality of life at 12 months (measured with MCS‐12, range: 0‐100, higher score = better health status) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.11 Quality of life at 24 months (measured with MCS‐12, range: 0‐100, higher score = better health status) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.12 Cure or improvement of bladder problems at 12 months (measured with UDI‐6, range: 0‐100, higher score = worse symptoms) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.13 Cure or improvement of bladder problems at 24 month (measured with UDI‐6, range: 0‐100, higher score = worse symptoms) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.14 Cure or improvement of bowel problems at 12 months (measured with CRADI‐8, range: 0‐100, higher score = worse symptoms) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.15 Cure or improvement of bowel problems at 24 months (measured with CRADI‐8, range: 0‐100, higher score = worse symptoms) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.16 Cure or improvement of sexual problems at 12 months (measured with PISQ‐12, range: 0‐48, higher score = better sexual functioning) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.17 Cure or improvement of sexual problems at 24 months (measured with PISQ‐12, range: 0‐48, higher score = better sexual functioning) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
2.18 Number of women with adverse events |
1 |
97 |
Risk Ratio (M‐H, Fixed, 95% CI) |
75.25 [4.70, 1205.45] |